| 0 (0%) | 09-27 11:13 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.39 | 1-year : | 2.59 |
| Resists | First : | 2.04 | Second : | 2.22 |
| Pivot price | 1.82  |
|||
| Supports | First : | 1.76 | Second : | 1.47 |
| MAs | MA(5) : | 1.8 |
MA(20) : | 1.87 |
| MA(100) : | 1.95 |
MA(250) : | 1.98 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 9 |
D(3) : | 8.9 |
| RSI | RSI(14): 44.4 |
|||
| 52-week | High : | 2.78 | Low : | 1.5 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ENTX ] has closed above bottom band by 45.5%. Bollinger Bands are 41% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.92 - 1.93 | 1.93 - 1.94 |
| Low: | 1.76 - 1.77 | 1.77 - 1.78 |
| Close: | 1.8 - 1.82 | 1.82 - 1.83 |
Thu, 25 Sep 2025
Entera Bio stock rating reiterated at Buy by H.C. Wainwright By Investing.com - Investing.com Nigeria
Thu, 18 Sep 2025
Entera Bio Unveils Promising PK Data for First Oral GLP-2 Therapy - sharewise.com
Mon, 15 Sep 2025
Entera Bio Reports Positive PK Data For Oral GLP-2 Tablet For Short Bowel Syndrome At 2025 ESPEN Congress - TradingView
Fri, 12 Sep 2025
Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Update - MarketBeat
Mon, 08 Sep 2025
4.4% Bone Density Improvement: Entera Bio's Oral Tablet Matches Injectable Osteoporosis Drugs in Phase 2 - Stock Titan
Fri, 22 Aug 2025
Market Brief: After Viking Therapeutics’ Results, Is Entera Bio the Oral Platform Play to Watch? (NASDAQ: ENTX) - FinancialContent
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 2.877e+007 (%) |
| Held by Institutions | 24.3 (%) |
| Shares Short | 55 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.055e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -6 % |
| Return on Assets (ttm) | 378.9 % |
| Return on Equity (ttm) | -44.6 % |
| Qtrly Rev. Growth | 166000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -48.66 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.04 |
| Price to Cash Flow | 6.99 |
| Dividend | 0 |
| Forward Dividend | 36430 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|